Table 1.

Characteristics of the Included Studies (continued)

Authors	Diabetes (I/C, %)	History of stroke (I/C, %)	Prior MI (I/C, %	Prior PCI (I/C, %)	Prior CABG (I/C, %)	Treated with PCI (I/C, %)	β-Blocker (I/C, %)	CCB (I/C, %)	ACEI/ARB (I/C, %)	Statin (I/C, %)	Nitrates (I/C, %)	PPI (I/C, %)	Bleeding Criteria	Study Quality
Kang et al14	29/30*	7/6*	12/18*	8/8*	1/2*	NA	52/57*	15/17*	62/65*	76/74*	NA	36/34*	PLATO	Low risk
Goto et al15	38/31	7/7	8/8	11/11	1/0	85/85	10/11	29/27	42/40	54/51	88/86	42/44	PLATO	Low risk
Wang et al16	42/39	11/10	17/15	3/6	0/0	75/71	69/74	69/63	61/67	83/79	90/89	31/33	PLATO	Low risk
Tang et al17	29/21	16/17	8/5	NA	NA	100/100	41/48	NA	38/47	99/100	86/88	NA	TIMI	Low risk
Park et al18	29/25	6/4	6/5	8/10	1/1	82/86	69/74	23/23	41/43	89/92	NA	3/2	PLATO	Low risk

I, intervention group; C, control group; BMI, body mass index; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; UA, unstable angina; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CCB, calcium channel blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; PPI, proton pump inhibitor; PLATO, platelet inhibition and patient outcomes trial; TIMI, thrombolysis in myocardial infarction; NA, not available; ^*data of all Asian population including East Asians and Southeast Asians; ^# P < .05.